1-3 of 3
Jeffrey Sawyer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma

Open Access
Clinical Trials & Observations
Samer Al Hadidi, Obada Ababneh, Carolina Schinke, Sharmilan Thanendrarajan, Clyde Bailey, Robert Smith, Susan Panozzo, Daisy Alapat, Guido Tricot, John Shaughnessy, Jr., Fenghuang Zhan, Jeffrey Sawyer, Eric R. Siegel, Bart Barlogie, Frits van Rhee, Maurizio Zangari
Journal: Blood Advances
Blood Adv (2025) 9 (4): 950–953.
https://doi.org/10.1182/bloodadvances.2024014889
Published: 2025
Includes: Supplemental data
Journal Articles

Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up

Free
Clinical Trials & Observations
Samer Al Hadidi, Obada Ehab Ababneh, Carolina D. Schinke, Sharmilan Thanendrarajan, Clyde Bailey, Robert Smith, Susan Panozzo, Daisy Alapat, Michele Cottler-Fox, Guido Tricot, John D. Shaughnessy, Jr., Fenghuang Zhan, Jeffrey Sawyer, Bart Barlogie, Maurizio Zangari, Frits van Rhee
Journal: Blood Advances
Blood Adv (2024) 8 (3): 703–707.
https://doi.org/10.1182/bloodadvances.2023011601
Published: 2024
Includes: Supplemental data
Journal Articles

Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma

Free
Clinical Trials & Observations
Meera Mohan, Samantha Kendrick, Aniko Szabo, Naveen Yarlagadda, Dinesh Atwal, Yadav Pandey, Arya Roy, Richa Parikh, James Lopez, Sharmilan Thanendrarajan, Carolina Schinke, Daisy Alapat, Jeffrey Sawyer, Erming Tian, Guido Tricot, Frits van Rhee, Maurizio Zangari
Journal: Blood Advances
Blood Adv (2022) 6 (3): 808–817.
https://doi.org/10.1182/bloodadvances.2021005822
Published: 2022
Includes: Supplemental data